FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895420512> ?p ?o ?g. }

• W2895420512 endingPage "3130" @default.
• W2895420512 startingPage "3115" @default.
• W2895420512 abstract "LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review Paola Rogliani,1 Luigino Calzetta,1 Fulvio Braido,2 Mario Cazzola,1 Enrico Clini,3 Girolamo Pelaia,4 Andrea Rossi,5 Nicola Scichilone,6 Fabiano Di Marco7 1Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy; 2Department of Internal Medicine, IRCCS San Martino Genoa University Hospital, Genoa, Italy; 3Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy; 4Department of Medical and Surgical Sciences, Section of Respiratory Diseases, Magna Græcia University, Catanzaro, Italy; 5Pulmonary Unit, University of Verona, Verona, Italy; 6Department of Internal Medicine, University of Palermo, Palermo, Italy; 7Department of Health Sciences, Università degli Studi di Milano, Respiratory Unit, Papa Giovanni XXIII Hospital, Bergamo, Italy Objectives: The aim of this study was to assess the current evidence for long-acting β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) in the treatment of COPD.Materials and methods: A systematic literature search of randomized controlled trials published in English up to September 2017 of LABA/LAMA FDCs vs LABA or LAMA or LABA/inhaled corticosteroid (ICS) FDCs in COPD patients was performed using PubMed, Embase, Scopus, and Google Scholar. Outcomes including forced expiratory volume in 1 second (FEV1), Transition Dyspnea Index (TDI) scores, St George’s Respiratory Questionnaire (SGRQ) scores, exacerbations, exercise tolerance (endurance time [ET]), inspiratory capacity (IC), and rescue medication use were evaluated.Results: In total, 27 studies were included in the review. LABA/LAMA FDCs significantly improved lung function (FEV1) at 12 weeks compared with LABA or LAMA or LABA/ICS. These effects were maintained over time. Significant improvements with LABA/LAMA FDCs vs each evaluated comparator were also observed in TDI and SGRQ scores, even if significant differences between different LABA/LAMA FDCs were detected. Only the LABA/LAMA FDC indacaterol/glycopyrronium has shown superiority vs LAMA and LABA/ICS for reducing exacerbation rates, while olodaterol/tiotropium and indacaterol/glycopyrronium have been shown to improve ET and IC vs the active comparators. Rescue medication use was significantly reduced by LABA/LAMA FDCs vs the evaluated comparators. LABA/LAMA FDCs were safe, with no increase in the risk of adverse events with LABA/LAMA FDCs vs the monocomponents.Conclusion: Evidence supporting the efficacy of LABA/LAMA FDCs for COPD is heterogeneous, particularly for TDI and SGRQ scores, exacerbation rates, ET, and IC. So far, indacaterol/glycopyrronium is the LABA/LAMA FDC that has the strongest evidence for superiority vs LABA, LAMA, and LABA/ICS FDCs across the evaluated outcomes. LABA/LAMA FDCs were safe; however, more data should be collected in a real-world setting to confirm their safety. Keywords: LABA, LAMA, fixed-dose combination, COPD, systematic review" @default.
• W2895420512 created "2018-10-12" @default.
• W2895420512 creator A5004648556 @default.
• W2895420512 creator A5018421075 @default.
• W2895420512 creator A5026357881 @default.
• W2895420512 creator A5035810516 @default.
• W2895420512 creator A5038898384 @default.
• W2895420512 creator A5053217610 @default.
• W2895420512 creator A5059461770 @default.
• W2895420512 creator A5060089859 @default.
• W2895420512 creator A5079548491 @default.
• W2895420512 date "2018-10-01" @default.
• W2895420512 modified "2023-09-25" @default.
• W2895420512 title "LABA/LAMA fixed-dose combinations in patients with COPD: a systematic review" @default.
• W2895420512 cites W1553966959 @default.
• W2895420512 cites W1637753636 @default.
• W2895420512 cites W1901890356 @default.
• W2895420512 cites W1950043623 @default.
• W2895420512 cites W1999225686 @default.
• W2895420512 cites W2026585673 @default.
• W2895420512 cites W2030987445 @default.
• W2895420512 cites W2039237831 @default.
• W2895420512 cites W2039566927 @default.
• W2895420512 cites W2056040906 @default.
• W2895420512 cites W2057335633 @default.
• W2895420512 cites W2061579085 @default.
• W2895420512 cites W2079608684 @default.
• W2895420512 cites W2096723137 @default.
• W2895420512 cites W2102367871 @default.
• W2895420512 cites W2104675861 @default.
• W2895420512 cites W2105234929 @default.
• W2895420512 cites W2106512669 @default.
• W2895420512 cites W2111815628 @default.
• W2895420512 cites W2112499866 @default.
• W2895420512 cites W2113302513 @default.
• W2895420512 cites W2116505643 @default.
• W2895420512 cites W2117943611 @default.
• W2895420512 cites W2123850585 @default.
• W2895420512 cites W2128278745 @default.
• W2895420512 cites W2128643475 @default.
• W2895420512 cites W2134820467 @default.
• W2895420512 cites W2142449488 @default.
• W2895420512 cites W2142724633 @default.
• W2895420512 cites W2142837436 @default.
• W2895420512 cites W2156831035 @default.
• W2895420512 cites W2161374186 @default.
• W2895420512 cites W2163317499 @default.
• W2895420512 cites W2163674202 @default.
• W2895420512 cites W2166685465 @default.
• W2895420512 cites W2167795093 @default.
• W2895420512 cites W2169278962 @default.
• W2895420512 cites W2233753101 @default.
• W2895420512 cites W2345974479 @default.
• W2895420512 cites W2346277111 @default.
• W2895420512 cites W2365138737 @default.
• W2895420512 cites W2496257167 @default.
• W2895420512 cites W2512002633 @default.
• W2895420512 cites W2520342023 @default.
• W2895420512 cites W2558903543 @default.
• W2895420512 cites W2565051425 @default.
• W2895420512 cites W2572235075 @default.
• W2895420512 cites W2580440154 @default.
• W2895420512 cites W2584879811 @default.
• W2895420512 cites W2587433062 @default.
• W2895420512 cites W2588681363 @default.
• W2895420512 cites W2588781854 @default.
• W2895420512 cites W2591678263 @default.
• W2895420512 cites W2593670800 @default.
• W2895420512 cites W2596492194 @default.
• W2895420512 cites W2608963101 @default.
• W2895420512 cites W2617995139 @default.
• W2895420512 cites W2738246554 @default.
• W2895420512 cites W2782011123 @default.
• W2895420512 cites W2783447022 @default.
• W2895420512 cites W2785999277 @default.
• W2895420512 cites W2795596093 @default.
• W2895420512 cites W2802221596 @default.
• W2895420512 cites W2804974357 @default.
• W2895420512 cites W2916841405 @default.
• W2895420512 cites W2991792334 @default.
• W2895420512 cites W332402261 @default.
• W2895420512 cites W349844564 @default.
• W2895420512 doi "https://doi.org/10.2147/copd.s170606" @default.
• W2895420512 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6174911" @default.
• W2895420512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30323582" @default.
• W2895420512 hasPublicationYear "2018" @default.
• W2895420512 type Work @default.
• W2895420512 sameAs 2895420512 @default.
• W2895420512 citedByCount "31" @default.
• W2895420512 countsByYear W28954205122019 @default.
• W2895420512 countsByYear W28954205122020 @default.
• W2895420512 countsByYear W28954205122021 @default.
• W2895420512 countsByYear W28954205122022 @default.
• W2895420512 countsByYear W28954205122023 @default.
• W2895420512 crossrefType "journal-article" @default.
• W2895420512 hasAuthorship W2895420512A5004648556 @default.
• W2895420512 hasAuthorship W2895420512A5018421075 @default.
• W2895420512 hasAuthorship W2895420512A5026357881 @default.

• next